Want to see IL:BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
1.50
0.10(6.67%)
At close: 4:00 PM EDT
1.50
0.10(6.67%)
Day’s Range― - ―
52-Week Range1.10 - 2.40
Previous CloseN/A
Volume0.00
Average Volume (3M)4.64M
Market Cap
₪41.94M
Enterprise Value21.57
Total Cash (Recent Filing)₪17.35M
Total Debt (Recent Filing)₪9.07M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 31, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,620,977,300
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)₪1.95M
Bulls Say, Bears Say
Bulls Say
APHEXDA Commercial TractionGrowing partner sales are converting into higher royalties without requiring BioLineRx to build a broad direct-sales infrastructure. Continued APHEXDA adoption could provide a recurring revenue stream and help diversify funding beyond equity or debt.
GLIX1 Clinical AdvancementMoving GLIX1 into human testing is a meaningful development milestone for BioLineRx’s oncology pipeline. The program’s blood-brain-barrier penetration and preclinical activity support potential differentiation, while clinical data can create future partnering or licensing opportunities.
Manageable LeverageModerate leverage and positive equity provide some financial resilience relative to a highly leveraged development-stage biotech. Although cash burn remains a concern, the current capital structure does not indicate excessive debt pressure on future clinical investment.
Bears Say
Persistent Deep LossesThe company’s revenue base remains far too small to cover research, development and corporate costs. Very large operating and net losses indicate that profitability is not yet established, leaving long-term results dependent on pipeline success and external financing.
Negative Cash GenerationBioLineRx is not currently funding operations internally, even though cash burn improved substantially from 2024. Continued negative free cash flow will consume liquidity as clinical programs advance and may require additional capital that could dilute shareholders.
PDAC Development UncertaintyChanging external treatment data could weaken motixafortide’s positioning in pancreatic cancer or require strategic adjustments to its development plan. This creates lasting uncertainty around trial value, future investment priorities and the commercial potential of the program.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.10 and its highest was 2.40 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪41.94M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 5 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on May 27, 2026. The company reported 0 earnings per share for the quarter, beating the consensus estimate of -0.6 by 0.6.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is 0.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,620,977,300 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report, beating expectations of -0.6. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.